Following this announcement, we reported a reduction in force of approximately 75% of our workforce, impacting 87 employees, in addition to other cost-saving measures in order to preserve capital, including the stoppage of commercialization efforts for LYR-210 and pausing development efforts for LYR-220, which is substantially similar to LYR-210 and also directed at patients living with CRS, but employs a larger impl

filing / Mar 31, 2026 / receipt

In addition, we reported that our Board approved a plan to suspend further development of LYR-210, the Company’s lead product candidate for the treatment of chronic rhinosinusitis, and to implement a cost reduction plan that included a workforce reduction impacting substantially all of the Company’s remaining employees, effective January 12, 2026, and other cost-saving actions to preserve capital.

filing / Mar 31, 2026 / receipt

• on January 9, 2026, our Board of Directors approved a plan to suspend further development of LYR-210, our lead product candidate for the treatment of chronic rhinosinusitis, and to implement a cost reduction plan that includes a workforce reduction impacting substantially all of our remaining employees, effective January 12, 2026, and other cost-saving actions to preserve capital;

filing / Mar 31, 2026 / receipt

We also announced a workforce reduction impacting 25 employees and other cost-saving actions to preserve capital. Maria Palasis, Ph.D., Chief Executive Officer, President and Chair of the Board, and Mr.

filing / Mar 31, 2026 / receipt

In December 2023, the Company executed a sublease agreement for additional laboratory and office space located at 880 Winter Street in Waltham.

filing / Mar 31, 2026 / receipt

In Waltham, Massachusetts we have a lease for laboratory, manufacturing and office space, which terminates in July 2033, and a sublease for laboratory and office space, which terminates in November 2032.

filing / Mar 31, 2026 / receipt